PMID- 37124269
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230502
IS  - 1664-0640 (Print)
IS  - 1664-0640 (Electronic)
IS  - 1664-0640 (Linking)
VI  - 14
DP  - 2023
TI  - Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory 
      survey among substance users.
PG  - 1096298
LID - 10.3389/fpsyt.2023.1096298 [doi]
LID - 1096298
AB  - BACKGROUND: Alcohol and other substance use disorders are commonly associated 
      with post-traumatic stress disorder (PTSD), and the presence of these 
      comorbidities is associated with worse treatment outcomes. Additionally, 
      disparities in substance and PTSD prevalence have been associated with minority 
      races and ethnicities, and minorities have been shown to be less likely to engage 
      in treatment. Psychedelic-assisted treatments, including 
      3,4-methylenedioxymethamphetamine (MDMA), have shown preliminary trans-diagnostic 
      effectiveness, however it is unknown how individuals with substance use disorders 
      view the therapeutic potential of MDMA therapy. Previous studies have also shown 
      that minority races and ethnicities are under-represented in the MDMA trials, 
      leading to concerns about inequitable access to clinical treatment. METHODS: To 
      explore demographic characteristics related to patient-level perspectives on the 
      therapeutic potential of MDMA-assisted therapy, this study describes data from a 
      nationwide, cross-sectional survey of 918 individuals self-reporting criteria 
      consistent with alcohol or substance use disorders. RESULTS: Overall, a majority 
      of individuals reported support for medical research of MDMA (68.1%), belief that 
      MDMA-assisted therapy might be a useful treatment (70.1%), and willingness to try 
      MDMA-assisted therapy if it were determined to be an appropriate treatment for 
      them (58.8%). No race or ethnicity differences were found in support for further 
      research or belief in effectiveness, however there were small disparities in 
      terms of willingness to try MDMA-assisted therapy and concerns related to use of 
      this treatment approach. CONCLUSION: These results provide insights and future 
      directions as the field of psychedelic-assisted therapy seeks to provide 
      equitable access to clinical care and to diversify research participation.
CI  - Copyright (c) 2023 Jones.
FAU - Jones, Jennifer L
AU  - Jones JL
AD  - Department of Psychiatry and Behavioral Sciences, Medical University of South 
      Carolina, Charleston, SC, United States.
LA  - eng
PT  - Journal Article
DEP - 20230414
PL  - Switzerland
TA  - Front Psychiatry
JT  - Frontiers in psychiatry
JID - 101545006
PMC - PMC10140372
OTO - NOTNLM
OT  - MDMA
OT  - PTSD
OT  - race and ethnicity
OT  - substance and alcohol use
OT  - treatment
COIS- The author declares that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/01 06:42
MHDA- 2023/05/01 06:43
PMCR- 2023/04/14
CRDT- 2023/05/01 03:41
PHST- 2022/11/11 00:00 [received]
PHST- 2023/03/23 00:00 [accepted]
PHST- 2023/05/01 06:43 [medline]
PHST- 2023/05/01 06:42 [pubmed]
PHST- 2023/05/01 03:41 [entrez]
PHST- 2023/04/14 00:00 [pmc-release]
AID - 10.3389/fpsyt.2023.1096298 [doi]
PST - epublish
SO  - Front Psychiatry. 2023 Apr 14;14:1096298. doi: 10.3389/fpsyt.2023.1096298. 
      eCollection 2023.